Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 5;58(2):211–225. doi: 10.3892/ijo.2021.5167

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Holzhauser et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Combinational effects of the PI3K inhibitor, BYL719, and FGFR inhibitor, JNJ-42756493, with cisplatin, vincristine and doxorubicin on SK-N-BE(2)-C and SK-N-SH cell lines. CIs were obtained by the highest single agent approach following treatment of (A and E) SK-N-BE(2)-C and (B and F) SK-N-SH cells with (A and B) BYL719 or (E and F) JNJ-42756493 and cytostatic drugs. CIs were calculated also only for BYL719 and cytostatic drugs by using the median effect method for (C) SK-N-BE(2)-C and (D) SK-N-SH cells, since for JNJ-42756493 r<0.85 in median method, so the analysis could not proceed. CIs were calculated from the mean of 3 experiments, analyzed by WST 1. o denotes CI >2, which shows a negative combination effect. CI, combination index; BYL, BYL719; JNJ, JNJ-42756493; CIS, cisplatin; VIN, vincristine; DOXO, doxorubicin.